Selecting Antibiotics For Skin Structure Infection Treatment
Arlington Medical Resources (AMR) and Decision Resources find that with the rising incidence of skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), an overwhelming majority of surveyed physicians indicate that the most important attribute influencing antibiotic selection in skin and skin structure infections (SSSIs) is activity against MRSA.
Other factors that influence drug selection include an agent's skin penetration and its ability to avoid the development of resistant pathogens.
"Physicians we surveyed also indicate that the two most important factors that influence hospital prescribing for SSSIs are recommendations from infectious disease consults and the Infectious Diseases Society of America (IDSA) guidelines. Clinicians treating patients with SSSIs look to these specialists and guidelines for direction when managing SSSI patients," stated John Lebbos, M.D., vice president of infectious diseases at Decision Resources.
The new report entitled Hospital Anti-Infectives Insight Series: Skin & Skin Structure Infections also finds that surveyed physicians state that the success of Pfizer's Zyvox and Cubist Pharmaceuticals' Cubicin is driven strongly by these agents' excellent activity against MRSA. Vancomycin remains the most commonly prescribed agent for empiric coverage of MRSA, and its use is largely driven by familiarity and local hospital guidelines. In contrast, surveyed physicians indicate that use of Zyvox and Cubicin is driven by product attributes, namely their excellent activity against MRSA activity.